Download PDF
Fortschr Neurol Psychiatr 2000; 68(7): 321-331
DOI: 10.1055/s-2000-11805
ORIGINALARBEIT
Georg Thieme Verlag Stuttgart · New York

Klinische Charakteristika von Patienten mit tardiven Dyskinesien

T. Held1 , T. Weber1 , H. Krausz2 , G. Ahle2 , B. Hager1 , D. Alfter2 , T. Schulze2 , M. Knapp3 , W. Maier2 , M. Rietschel2
  • 1Rheinische Kliniken, Bonn (Ärztl. Leiter: Prof. Dr. T. Held)
  • 2Klinik und Poliklinik für Psychiatrie und Psychotherapie der Rheinischen Friedrich-Wilhelms-Universität Bonn(Direktor: Prof. Dr. W. Maier)
  • 3Institut für Medizinische Biometrie, Informatik undEpidemiologie der Rheinischen Friedrich-Wilhelms-Universität Bonn (Direktor: Prof. Dr. M. P. Baur)
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

Zusammenfassung:

Wenngleich eine große Zahl von Arbeiten zum Zusammenhang zwischen tardiven Dyskinesien und Patientencharakteristika existiert, ist ihre Aussagekraft häufig durch mangelnde operationalisierte Phänotypisierung der Patienten und ihrer Befunde eingeschränkt. Speziell im Zusammenhang mit neurobiologischer und molekulargenetischer Fragestellung ist aber eine reliable Phänotypisierung von äußerster Bedeutung. 241 Patienten mit den DSM-IV-Diagnosen Schizophrenie und Schizoaffektive Störung wurden mit den Instrumenten SADS-L, OPCRIT, BPRS und PANSS untersucht. Zur Untersuchung der Motorik wurden an 2 unterschiedlichen Tagen innerhalb von 3 Monaten die Befunde mit folgenden Skalen erhoben: TDRS, AIMS, SAS, BAS. Die Diagnose „tardive Dyskinesie” wurde nach den Forschungskriterien von Schooler u. Kane gestellt. Die Lebenszeitmedikation mit Neuroleptika und Anticholinergika wurde möglichst genau quantitativ erfasst. Ergebnisse: 97 von 233 Probanden (= 41,6 %) wiesen tardive Dyskinesien auf. Bei der univariaten Analyse wiesen folgende unabhängige Variablen einen statistisch signifikanten Zusammenhang mit der Zielvariablen „persistent tardive dyskinesia” auf (stärkere Merkmalsausprägung = Risikofaktor): Alter (p = 0,001), Jahre seit Krankheitsbeginn (p = 0.001), Gesamtdauer stationärer Behandlung (p = 0,001), PANSS (Einzelskalen und Summenscore) (p = 0,0001), Neuroleptika-Gesamtdosis in CPZ-Äquivalenten (p = 0,004). Die logistische Regressionsanalyse ergab, dass einzig „Alter” und „Negativsymptomatik nach PANSS” einen Zusammenhang mit tardiven Dyskinesien aufweisen, der nicht durch die Kovariation mit anderen unabhängigen Variablen erklärbar ist. Wurde anstelle der dichotomen Zielvariablen „tardive Dyskinesien ja/nein” der Zahlenwert der TDRS-Skala gewählt, so ergaben sich dieselben Zusammenhänge. Unsere Arbeit verweist auf die Wichtigkeit, neurobiologische Korrelate von „Alter” und „Negativsymptomatik” in Bezug auf die Disposition zu tardiven Dyskinesien zu suchen.

Clinical Characteristics of Patients with Tardive Dyskinesia:

Although there is a great number of studies on the relationship between tardive dyskinesia and patient characteristics, too often their validity is impaired by the lack of operationalized criteria for the description of patients and signs. Reliable phenotyping is of utmost importance for linking clinical data with data from methods in neurobiology or molecular genetics. 241 patients with the DSM IV diagnosis “schizophrenia” or “schizoaffective disorder” were examined with the instruments SADS-L, OPCRIT, BPRS and PANSS. Motor phenomena were analyzed on 2 separate days within 3 months with the scales TDRS, AIMS, SAS, BAS. Tardive dyskinesia was diagnosed following the research criteria of Schooler and Kane. Lifetime medication with neuroleptics and anticholinergic drugs was assessed quantitatively. Results: 97 out of 233 patients (= 41,6 %) displayed persistent tardive dyskinesia. In univariate analysis, signifikant associations were found between tardive dyskinesia and the following independent variables (higher values means greater risk): Age (p = 0,0001), years from onset of the disorder (p = 0,001), total length of stay in hospital (p = 0,001), PANSS (single scales and sum score) (p = 0,0001), total amount of neuroleptics expressed as CPZ equivalents (p = 0,004). Logistic regression analysis showed that only the variables “age” and “negative symptoms” expressed as score on the PANSS negative subscale showed an association with tardive dyskinesia that could not be explained by covariation with other variables. The same results were found when, instead of the dichotomous variable “tardive dyskinesia yes/no” the associations with the TDRS score were analyzed. Future research should aim to approach the neurobiological correlates of “age” and “negative symptoms” in relationship to tardive dyskinesia.

Literatur

  • 1 Schönecker M. Ein eigentümliches Syndrom im oralen Bereich bei Megaphenapplikation.  Nervenarzt. 1957;  28 35
    PubMedGoogle Scholar
  • 2 American Psychiatric Association .Tardive dyskinesia: A Task Force Report of the American Psychiatric Association. Washington DC 1992
    Google Scholar
  • 3 Jeste D V, Caligiuri M P, Paulsen J S, Heaton R K, Lacro J P, Harris M J, Bailey A, Fell R L, McAdams L A. Risk of tardive dyskinesia in older patients.  Arch Gen Psychiatry 52 (1995). 1995;  52 756-765
    PubMedGoogle Scholar
  • 4 Kraepelin E. Psychiatry II. Band Klinische Psychiatrie, 7. Auflage. Leipzig: Johann Ambrosius Barth 1904: 188-189
    Google Scholar
  • 5 Fenton W S, Wyatt R J, McGlashan T H. Risk factors for spontaneous dyskinesia in schizophrenia.  Arch Gen Psychiatry. 1994;  51 643-650
    PubMedGoogle Scholar
  • 6 Chatterjee A, Chakos M, Koreen A, Geisler S, Sheitman B, Woerner M, Kane J M, Alvir J, Lieberman J A. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients.  Am J Psychiatry. 1995;  152 1724-1729
    PubMedGoogle Scholar
  • 7 Gervin M, Browne S, Lane A, Clarke M, Waddington J L, Larkin C, O'Callaghan E. Spontaneous abnormal involuntary movements in first-episode schizophrenia and schizophreniform disorder: baseline rate in a group of patients from an Irish catchment area.  Am J Psychiatry. 1998;  155 1202-1206
    PubMedGoogle Scholar
  • 8 Villeneuve A, Turcotte J, Bouchard M, Cote J M, Jus A. Release phenomena and interactive activities in psychiatric geriatric patients.  Can Med Assoc J. 1974;  110 147-153
    PubMedGoogle Scholar
  • 9 Kane J M, Smith M. Tardive dyskinesia.  Arch Gen Psychiatry. 1982;  39 473-481
    CrossrefPubMedGoogle Scholar
  • 10 Barnes T RE, Rossor M, Trauer T. A comparison of purposeless movements in psychiatric patients treated with antipsychotic drugs, and normal individuals.  J Neurol Neurosurg Psychiatry. 1983;  46 540-546
    PubMedGoogle Scholar
  • 11 Lieberman J, Kane J M, Woerner M, Weinhold P. Prevalence of tardive dyskinesia in elderly samples.  Psychopharmacol Bulletin. 1984;  20 381-386
    PubMedGoogle Scholar
  • 12 Yassa R, Jeste D V. Gender differences in tardive dyskinesia: a critical review of the literature.  Schizophr Bull. 1993;  18 701-715
    PubMedGoogle Scholar
  • 13 Albus M, Naber D, Müller-Spahn F, Douillet P, Reinertshofer T, Ackenheil M. Tardive dyskinesia: relation to computer-tomographic, endocrine and psychopathological variables.  Biol Psychiatry. 1985;  20 1082-1089
    CrossrefPubMedGoogle Scholar
  • 14 Bartels M, Greil W, Haag H, Hippius H, Rüther E, Pflug B. Neuroleptika als Ursache für Spätdyskinesien: Klinische Relevanz und Prävention.  Deutsches Ärzteblatt. 1985;  82 1787-1790
    PubMedGoogle Scholar
  • 15 Greil W, Haag H, Rüther E. Untersuchungen zur Entstehung und Behandlung von Spätdyskinesie. In: Hippius H, Rüther E, Schmauß M (Hrsg). Katatone und dyskinetische Syndrome Berlin, Heidelberg, New York, London, Paris, Tokyo, Hongkong: Springer Verlag 1989: 213-223
    Google Scholar
  • 16 Haag H, Greil W, Haag M, Bender W, Rüther E. Tardive dyskinesia and medication history.  Pharmacopsychiat. 1985;  18 35-36
    PubMedGoogle Scholar
  • 17 Haag H, Greil W, Rüther E. Zusammenhang zwischen Spätdyskinesie und verschiedenen Variablen der neuroleptischen Behandlung. In: Heinrich K, Klieser E (Hrsg). Probleme der neuroleptischen Dosierung Stuttgart, New York: Schattauer 1987: 237-257
    Google Scholar
  • 18 Kulhanek F. Was wissen wir über die Beziehung der neuroleptischen Therapie zu Prävalenz, Inzidenz und Persistenz der Spätdyskinesien.  In: Lange E, Hoffmann W. 6. Dresdner Symposium zu aktuellen Fragen der Psychopharmakotherapie Jena-Stuttgart: Gustav Fischer 1994: 156-180
    Google Scholar
  • 19 von Oefele K, Erice-Keppler E, Grohmann R, Rüther E. Häufigkeit und Schweregrad von Spätdyskinesien bei psychiatrischen Langzeitpatienten.  Nervenheilkunde. 1989;  8 222-227
    PubMedGoogle Scholar
  • 20 Rittmannsberger H, Schöny W. Prävalenz tardiver Dyskinesie bei langzeit-hospitalisierten schizophrenen Patienten.  Nervenarzt. 1986;  57 116-118
    PubMedGoogle Scholar
  • 21 Schooler N R, Kane J M. Research diagnosis for tardive dyskinesia.  Arch Gen Psychiatry. 1982;  39 486-487
    PubMedGoogle Scholar
  • 22 Altamura A C, Cavallaro R, Regazzetti M G. Prevalence and risk factors for tardive dyskinesia: a study in an Italian population of chronic schizophrenics.  Eur Arch Psychiatry Clin Neurosci. 1990;  240 p09-12
    PubMedGoogle Scholar
  • 23 Bailey L G, Maxwell S, Brandabur M M. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients.  Psychopharmacol Bull. 1997;  33 177-181
    PubMedGoogle Scholar
  • 24 Bergen J, Kitchin R, Berry G. Predictors of the course of tardive dyskinesia in patients receiving neuroleptics.  Biol Psychiatry. 1992;  32 580-594
    CrossrefPubMedGoogle Scholar
  • 25 Cavallaro R, Regazzetti M G, Mundo E, Brancato V, Smeraldi E. Tardive dyskinesia outcomes: Clinical and pharmacologic correlates of remission and persistence.  Neuropsychopharmacology. 1993;  8 233-239
    PubMedGoogle Scholar
  • 26 Chiu H, Shun P, Lau J, Lam L, Lee S. Prevalence of tardive dyskinesia, tardive dystonia, and respiratory dyskinesia among chinese psychiatric patients in Hong Kong.  Am J Psychiatry. 1992;  149 1081-1985
    PubMedGoogle Scholar
  • 27 Cohen S, Khan A, Zheng Y, Chiles J. Tardive dyskinesia in the mentally retarded: comparison of prevalence, risk factors and topography with a schizophrenic population.  Acta Psychiatr Scand. 1991;  83 234-237
    PubMedGoogle Scholar
  • 28 Glazer W M, Morgenstern H, Doucette J T. The prediction of chronic persistent versus intermittent tardive dyskinesia. A retrospective follow-up study.  Br J Psychiatry. 1991;  158 822-828
    PubMedGoogle Scholar
  • 29 Harris M J, Panton D, Caligiuri M P, Krull A J, Tran-Johnson T K, Jeste D V. High incidence of tardive dyskinesia in older outpatients on low doses of neuroleptics.  Psychopharmacol Bull. 1992;  28 87-92
    PubMedGoogle Scholar
  • 30 Inada T, Ohnishi K, Kamisada M, Matsuda G, Tajima O, Yanagisawa Y, Hashiguchi K, Shima S, Oh-e Y, Masuda Y, Chiba T, Kamijima K, Rockhold R W, Yagi G. A prospective study of tardive dyskinesia in Japan.  Eur Arch Psychiatry Clin Neurosci. 1991;  240 250-254
    PubMedGoogle Scholar
  • 31 Jeste D V, Caligiuri M P. Tardive dyskinesia.  Schizophr Bull. 1993;  19 303-315
    CrossrefPubMedGoogle Scholar
  • 32 Kane J M, Woerner M, Lieberman J. Tardive dyskinesia: prevalence, incidence, and risk factors.  J Clinical Psychopharmacol. 1988;  8 52S-56S
    PubMedGoogle Scholar
  • 33 Kay S R, Fiszbein A, Opler L A. The positive and negative syndrome scale.  Schizophr Bull. 1987;  13 261-276
    CrossrefPubMedGoogle Scholar
  • 34 Liddle P F, Barnes T RE, Speller J, Kibel D. Negative symptoms as a risk factor for tardive dyskinesia in schizophrenia.  Br J Psychiatry. 1993;  163 776-780
    PubMedGoogle Scholar
  • 35 McCreadie R G, Robertson L J, Wiles D H. The Nithsdale schizophrenia surveys. IX: Akathisia, parkinsonism, tardive dyskinesia and plasma neuroleptic levels.  Br J Psychiatry. 1992;  161 793-799
    PubMedGoogle Scholar
  • 36 Miller C H, Simoni I, Oberbauer H, Schwitzer J, Barnas C, Kulhanek F, Boissel K E, Meise U, Hinterhuber H, Fleischhacker W. Tardive dyskinesia prevalence rates during a ten-year follow-up.  J Nerv Ment Dis. 1995;  183 404-407
    PubMedGoogle Scholar
  • 37 Morgenstern H, Glazer W M. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.  Arch Gen Psychiatry. 1993;  50 723-733
    PubMedGoogle Scholar
  • 38 Muscettola G, Pampallona S, Barbato G, Casielle M, Bollini P. Persistent tardive dyskinesia: demographic and pharmacological risk factors.  Acta Psychiatr Scand. 1993;  87 29-36
    PubMedGoogle Scholar
  • 39 van Os J, Fahy T, Jones P, Harvey I, Toone B, Murray R. Tardive dyskinesia: who is at risk.  Acta Psychiatr Scand. 1997;  96 206-216
    PubMedGoogle Scholar
  • 40 Rosengarten H, Schweitzer J W, Friedhoff A J. Possible genetic factors underlying the pathophysiology of tardive dyskinesia.  Pharmacology Biochemistry and Behavior. 1994;  49 663-667
    CrossrefPubMedGoogle Scholar
  • 41 Sachdev P, Hume F, Toohey P, Doutney C. Negative symptoms, cognitive dysfunction, tardive akathisia and tardive dyskinesia.  Acta Psychiatr Scand. 1996;  93 451-459
    PubMedGoogle Scholar
  • 42 Schwartz M, Silver H, Tal I, Sharf B. Tardive dyskinesia in Northern Israel: Preliminary study.  Euro Neurol. 1993;  33 264-266
    PubMedGoogle Scholar
  • 43 Sweet R A, Mulsant B H, Gupta B, Rifai A H, Pasternak R E, McEachran A, Zubenko G S. Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life.  Arch Gen Psychiatry. 1995;  52 478-486
    PubMedGoogle Scholar
  • 44 Woerner M, Kane J M, Lieberman J A, Alvir J, Bergmann K J, Borenstein M, Schooler N R, Mukherjee S, Rotrosen J, Rubinstein M, Basavaraju N. The prevalence of tardive dyskinesia.  J Clin Psychopharmacol. 1991;  11 34-42
    PubMedGoogle Scholar
  • 45 Yuen O, Caligiuri M P, Williams R, Dickson R A. Tardive dyskinesia and positive and negative symptoms of schizophrenia. A study using instrumental measures.  Br J Psychiatry. 1996;  168 702-708
    PubMedGoogle Scholar
  • 46 Chouinard G, Annable L, Ross-Chouinard A, Nestoros J N. Factors related to tardive dyskinesia.  Am J Psychiatry. 1979;  136 79-83
    PubMedGoogle Scholar
  • 47 Gardos G, Casey D, Cole J O, Perenyi A, Kocsis E, Arato M, Samson J A, Conley C. Ten-year outcome of tardive dyskinesia.  Am J Psychiatry. 1994;  151 836-841
    PubMedGoogle Scholar
  • 48 Jeste D V, Wyatt R J. Understanding and treating tardive dyskinesia. New York: Guilford Press 1982
    Google Scholar
  • 49 Waddington J L, O'Callaghan E, Buckley P, Madigan C, Redmond O, Stack J P, Kinsella A, Larkin C, Ennis J T. Tardive dyskinesia in schizophrenia. Relationship to minor physical anomalies, frontal lobe dysfunction and cerebral structure of magnetic resonance imaging.  Br J Psychiatry. 1995;  167 41-44
    PubMedGoogle Scholar
  • 50 Glazer W M, Morgenstern H, Doucette J T. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medication.  J Clin Psychiatry. 1993;  54 133-139
    PubMedGoogle Scholar
  • 51 Pourcher E, Cohen H, Cohen D, Baruch P, Bouchard R H. Organic brain dysfunction and cognitive deficits in young schizophrenic patients with tardive dyskinesia.  Brain Cogn. 1993;  23 81-87
    PubMedGoogle Scholar
  • 52 Richardson M A, Haugland G, Craig T J. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients.  Am J Psychiatry. 1991;  148 1322-1328
    PubMedGoogle Scholar
  • 53 Toenniessen L M, Casey D E, McFarland B H. Tardive dyskinesia in the aged.  Arch Gen Psychiatry. 1985;  42 278
    PubMedGoogle Scholar
  • 54 Gardos G, Cole J O, Haskell D, Marby D, Paine S S, Moore P. The natural history of tardive dyskinesia.  Journal of Clinical Psychopharmacology. 1988;  8 (Suppl) 318-378
    PubMedGoogle Scholar
  • 55 Gardos G, Cole J O. The evaluation and treatment of neuroleptic-induced movement disorders.  Harv Rev Psychiatry. 1995;  3 130-139
    PubMedGoogle Scholar
  • 56 Tan C H, Tay L K. Tardive Dyskinesia in Elderly Psychiatric Patients in Singapore.  Aust Psychiatry. 1991;  25 119-122
    PubMedGoogle Scholar
  • 57 Joseph A B. Non-right-handedness and maleness correlate with tardive dyskinesia among patients taking neuroleptics.  Acta Psychiatr Scand. 1990;  81 530-533
    PubMedGoogle Scholar
  • 58 Kane J M, Rifkin A, Woerner M. Low-dose neuroleptic treatment of outpatient schizophrenics.  Arch Gen Psychiatry. 1983;  40 893-896
    PubMedGoogle Scholar
  • 59 Kane J M, Woerner M, Sarantakos S, Kinon B, Lieberman J. Do low-dose neuroleptics prevent or ameliorate tardive dyskinesia.  In: Dasey DE (ed.). Tardive dyskinesia and Neuroleptics: From Dogma to Reason Washington DC: American Psychiatric Press 1985: 99-108
    Google Scholar
  • 60 Chiu H FK, Wing Y K, Kwong P K, Leung C M. Prevalence of tardive dyskinesia in samples of elderly people in Hong Kong.  Acta Psychiatr Scand. 1993;  87 266-268
    PubMedGoogle Scholar
  • 61 Koshino Y, Madokoro S, Ito T, Horie T, Mukai M, Isaki K. A survey of tardive dyskinesia in psychiatric inpatients in Japan.  Clin Neuropharmacol. 1992;  15 34-43
    PubMedGoogle Scholar
  • 62 Sramek J, Roy S, Ahrens T, Pinanong P, Cutler N R, Pi E. Prevalence of tardive dyskinesia among three ethnic groups of chronic psychiatric patients.  Hospital and Community Psychiatry. 1991;  42 590-592
    PubMedGoogle Scholar
  • 63 Caligiuri M P, Lacro J P, Rockwell E, McAdams L A, Jeste D V. Incidence and risk factors for severe tardive dyskinesie in older patients.  Br J Psychiatry. 1997;  171 148-153
    PubMedGoogle Scholar
  • 64 Chen E YH, Lam L CW, Chen R YL, Nguyen D GH. Negative symptoms, neurological signs and neuropsychological impairments in 204 Hong Kong chinese patients with schizophrenia.  Br J Psychiatry. 1996;  168 227-233
    PubMedGoogle Scholar
  • 65 Davis E J, Borde M, Sharma L N. Tardive dyskinesia and type II schizophrenia.  Br J Psychiatry. 1992;  160 253-256
    PubMedGoogle Scholar
  • 66 Waddington J L, Youssef H A. An unusual cluster of tardive dyskinesia in schizophrenia: association with cognitive dysfunction and negative symptoms.  Am J Psychiatry. 1986;  143 1162-1165
    PubMedGoogle Scholar
  • 67 Dixon L, Weiden P J, Haas G, Sweeney J, Frances A J. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients.  Compr Psychiatry. 1992;  33 121-122
    CrossrefPubMedGoogle Scholar
  • 68 Duke P J, Pantelis C, Barnes T RE. South Westminster schizophrenia survey alcohol use and its relationship to symptoms, tardive dyskinesia and illness onset.  Br J Psychiatry. 1994;  164 630-636
    PubMedGoogle Scholar
  • 69 Olivera A A, Kiefer M W, Manley N K. Tardive dyskinesia in psychiatric patients with substance use disorders.  Am J Drug Alcohol Abuse. 1990;  16 57-66
    PubMedGoogle Scholar
  • 70 Paulsen J S, Caligiuri M P, Palmer B, AcAdams L A, Jeste D V. Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: a prospective longitudinal study.  Psychopharmacology (Berl.). 1996;  123 307-314
    PubMedGoogle Scholar
  • 71 McCreadie R G, Thara R, Kamath S, Padmavathy R, Latha S, Mathrubootham N, Menon M S. Abnormal movements in never-medicated indian patients with schizophrenia.  Br J Psychiatry. 1996;  168 221-226
    PubMedGoogle Scholar
  • 72 Sweet R A, Mulsant B H, Rifai A H, Zubenko G S. Dyskinesia and neuroleptic exposure in elderly psychiatric inpatients.  J Geriatr Psychiatry Neurol. 1992;  5 156-161
    PubMedGoogle Scholar
  • 73 O'Callaghan E, Larkin C, Kinsella A, Waddington J L. Obstetric complications, the putative familial-sporadic distinction, and tardive dyskinesia in schizophrenia.  Br J Psychiatry. 1990;  157 578-584
    PubMedGoogle Scholar
  • 74 Waddington J L, Youssef H A. Cognitive dysfunction in chronic schizophrenia followed prospectively over 10 years and its longitudinal relationship to the emergence of tardive dyskinesia.  Psychol Med. 1996;  26 681-688
    PubMedGoogle Scholar
  • 75 Richardson M A, Pass T, Bregman Z, Craig T J. Tardive dyskinesia and depressive symptoms in schizophrenics.  Psychopharmacol Bull. 1985;  21 130-135
    PubMedGoogle Scholar
  • 76 Yassa R, Nastase C, Dupont D, Thibeau M. Tardive dyskinesia in elderly psychiatric patients: a 5-year study.  Am J Psychiatry. 1992;  149 1206-1211
    PubMedGoogle Scholar
  • 77 Gardos G, Cole J. Tardive dyskinesia and anticholinergic drugs.  Am J Psychiatry. 1982;  140 200-202
    PubMedGoogle Scholar
  • 78 Ganzini L, Heintz R T, Hoffmann W F, Casey D E. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics.  Arch Gen Psychiatry. 1991;  48 259-263
    PubMedGoogle Scholar
  • 79 Mukherjee S, Wisniewski A, Bilder R, Sackeim H A. Possible association between tardive dyskinesia and altered carbohydrate metabolism (letter).  Arch Gen Psychiatry. 1985;  42 205
    PubMedGoogle Scholar
  • 80 Woerner M, Saltz B L, Kane J M, Lieberman J A, Alvir J MJ. Diabetes and development of tardive dyskinesia.  Am J Psychiatry. 1993;  150 966-968
    PubMedGoogle Scholar
  • 81 Casey D E. Tardive dyskinesia: pathophysiology. In: Bloom FE, Kupfer DJ. Psychopharmacology: The Fourth Generation of Progress New York: Raven Press 1995: 1497-1509
    Google Scholar
  • 82 Saltz B L, Woerner M G, Kane J M, Lieberman J A, Alvir J MJ, Bergmann K J, Blank K, Koblenzer J, Kahaner K. Prospective study of tardive dyskinesia: incidence in the elderly.  JAMA. 1991;  266 2402-2406
    CrossrefPubMedGoogle Scholar
  • 83 Kern R S, Green M F, Satz P, Wirshing W C. Patterns of manual dominance in patients with neuroleptic-induced movement disorders.  Biol Psychiatry. 1991;  30 483-492
    CrossrefPubMedGoogle Scholar
  • 84 Morgenstern H, Glazer W M, Doucette J T. Handedness and the risk of tardive dyskinesia.  Biol Psychiatry. 1996;  40 35-42
    CrossrefPubMedGoogle Scholar
  • 85 McCreadie R G. The Nithsdale schizophrenia surveys.  Soc Psychiatry Epidemiol. 1992;  27 40-45
    CrossrefPubMedGoogle Scholar
  • 86 Pourcher E, Baruch P, Bouchard R H, Filteau M J, Bergeron D. Neuroleptic associated tardive dyskinesia in young people with psychoses.  Br J Psychiatry. 1995;  166 768-772
    PubMedGoogle Scholar
  • 87 Waddington J L, Youssef H A. The lifetime outcome and involuntary movements of schizophrenia never treated with neuroleptic drugs.  Br J Psychiatry. 1990;  156 106-108
    PubMedGoogle Scholar
  • 88 Myers D E, Schooler N R, Zullo T G, Levin H. A retrospective study of the effects of edentulism on the severity rating of tardive dyskinesia.  J Prosthet Dent. 1993;  69 578-581
    PubMedGoogle Scholar
  • 89 Sandyk R, Kay S R, Awerbuch G I. Subjective awareness of abnormal involuntary movements in schizophrenia.  Int J Neurosci. 1993;  69 1-20
    PubMedGoogle Scholar
  • 90 Chakos M H, Alvir J M, Woerner M G, Koreen A, Geisler S, Mayerhoff D, Sobel S, Kane J M. Incidence and correlates of tardive dyskinesia in first episode of schizophrenia.  Arch Gen Psychiatry. 1996;  53 313-319
    PubMedGoogle Scholar
  • 91 Thomas P, McGuire R. Orofacial dyskinesia, cognitive function and medication.  Br J Psychiatry. 1986;  149 216-220
    PubMedGoogle Scholar
  • 92 Sandyk R, Kay S R. „Positive” and „negative” movement disorders in schizophrenia.  Int J Neurosci. 1992;  66 143-151
    PubMedGoogle Scholar
  • 93 Zaretsky A, Rector A A, Semann M V, Fornazzari X. Current cannabis use and tardive dyskinesia.  Schizophr Res. 1993;  11 3-8
    CrossrefPubMedGoogle Scholar
  • 94 Binder R L, Kazamatsuri H, Nishimura T, McNiel D E. Smoking and tardive dyskinesia.  Biol Psychiatry. 1987;  22 1280-1282
    CrossrefPubMedGoogle Scholar
  • 95 Yassa R, Lal S, Korpassy A, Ally J. Nicotine exposure and tardive dyskinesia.  Society of Biological Psychiatry. 1987;  22 67-72
    PubMedGoogle Scholar
  • 96 Raja M, Azzoni A. Tardive dystonia. Prevalence, risk factors and clinical features.  Ital J Neurol Sci. 1966;  17 409-418
    PubMedGoogle Scholar
  • 97 Yassa R, Nair V, Schwartz G. Early versus late onset psychosis and tardive dyskinesia.  Biol Psychiatry. 1986;  21 1291-1297
    CrossrefPubMedGoogle Scholar
  • 98 Endicott J, Spitzer R I. A diagnostic interview: the Schedule for Affective Disorder and Schizophrenia.  Arch Gen Psychiatry. 1978;  35 837-844
    PubMedGoogle Scholar
  • 99 Craddock N, Asherson P, Owen M J, Williams J, McGuffin P, Farmer A E. Concurrent validity of the OPCRIT diagnostic system: comparison of OPCRIT diagnoses with consensus best-estimate lifetime diagnoses.  B J Psychiatry. 1996;  169 58-63
    PubMedGoogle Scholar
  • 100 Overall J E, Gorham D R. The Brief Psychiatric Rating Scale.  Psychological Reports. 1962;  10 799-812
    CrossrefPubMedGoogle Scholar
  • 101 Simpson G M, Lee J H, Zubeck B, Gardos G. A rating scale for tardive dyskinesia.  Psychopharmacology. 1979;  64 171-179
    CrossrefPubMedGoogle Scholar
  • 102 Guy W. Abnormal Involuntary Movement Scale. In: ECDEU Assessment Manual for Psychopharmacology Washington DC: US Public Health Service 1976: 534-537
    Google Scholar
  • 103 Simpson G M, Angus J WS. A rating scale for extrapyramidal side effects.  Acta Psychiatr Scand. 1970;  Suppl. 212 11-19
    PubMedGoogle Scholar
  • 104 Barnes T RE, Braude W M. Akanthisia variants and tardive dyskinesia.  Arch Gen Psychiatry. 1985;  42 874-878
    PubMedGoogle Scholar
  • 105 Möller H J, Kissling W, Stoll K D, Wendt G. Psychopharmakotherapie. Stuttgart: Kohlhammer 1993: 218
    Google Scholar
  • 106 Andreasen N C, Olsen S A. Negative vs. positive schizophrenia.  Arch Gen Psychiatry. 1982;  39 789-794
    CrossrefPubMedGoogle Scholar

Prof. Dr. T. Held

Rheinische Kliniken Bonn

Kaiser-Karl-Ring 20
53111 Bonn

      >